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PREVEnTIOn
Why does diabetic retinopathy 
happen, and how can we stop it?
Diabetic retinopathy (DR) is a 
complication of diabetes. We 
can prevent DR both by 
preventing diabetes (primary 
prevention) and by improving 
the management of diabetes 
to slow down the onset, and 
reduce the severity, of DR 
(secondary prevention).
Primary	prevention
There is little that can be done 
to prevent type 1 diabetes. Its 
cause is uncertain and there 
is no evidence that any inter-
vention can prevent it. 
The vast majority of the 300 million 
people with diabetes have type 2 
diabetes, which is often preventable. 
There is good evidence that lifestyle 
changes, such as losing weight, 
increasing physical activity, and eating 
more fruit and vegetables can lead to a 
significant reduction in the incidence of 
type 2 diabetes. 
As diabetes is a cause of visual 
impairment, we should work with existing 
public health 
programmes and also 
ensure that diabetes is 
included in our eye care 
programmes. Eye care 
workers should take 
every opportunity to 
reinforce public health 
messages about 
avoiding obesity and 
taking regular exercise, 
and advise patients 
about weight loss and diet where 
possible. In addition, our specialist input 
might be valuable to the public health 
campaign, as avoiding blindness could be 
a powerful motivator for people to change 
their lifestyle for the better. 
Secondary	prevention
Optimal	blood	sugar	control
Good blood sugar (glycaemic) control can 
reduce the risk of retinopathy in anyone 
with diabetes.
type 1 diabetes. The Diabetes Control 
and Complications Trial followed two 
groups of people with type 1 diabetes, 
one that was intensively treated to control 
blood sugar and one that was managed in 
the usual way. After nine years they found 
a 26% reduction in the risk of development 
and progression of DR in the intensively 
treated group. 
type 2 diabetes. The United Kingdom 
Prospective Diabetes Study (UKPDS), 
published in 1997, showed that tight 
blood sugar control reduced the risk of 
progression of retinopathy and the need 
for laser treatment in people with type 2 
diabetes. This study 
showed a 16% reduction 
in the risk of legal 
blindness in the inten-
sively treated group 
compared to usual 
management at ten 
years. 
In practice, however, 
perfect blood sugar 
control is unattainable in 
patients with type 1 
diabetes because of the 
risk of unpredictable hypoglycaemia. With 
type 2 diabetes, most patients do not 
achieve tight control and if they do it 
tends to deteriorate with time. 
Control	of	blood	pressure
In patients with high blood pressure 
(hypertension), control of blood pressure 
can reduce the risk of developing DR. The 
UKPDS randomised hypertensive patients 
with diabetes to two different groups:
•	tight blood pressure control (<150/85 
mmHg) using predominantly a 
beta-blocker or an angiotensin 
converting enzyme (ACE) inhibitor with 
the addition of other agents if required
•	less tight blood 
pressure control 
(<180/105 mmHg) 
without the use of 
beta-blockers or ACE 
inhibitors.  
After seven years, there 
was a 35% reduction in the 
progression of DR in the 
tight blood pressure control 
group.  At nine years, the 
tight blood pressure control 
group showed a 47% 
reduction in the risk of 
moderate visual loss and a 
35% reduction in the need 
for laser treatment.  The 
study found no benefit of the 
ACE inhibitor (captopril) over 
the beta-blocker (atenolol).  
Several large studies have looked at 
the effect of individual ACE inhibitors in 
patients with diabetes. However, the 
effect on DR has been, at best, a 
secondary outcome measure and there is 
no clear evidence that one method of 
lowering blood pressure is superior to 
another in terms of its effectiveness in 
slowing down the progression of DR.
The Diabetic Retinopathy 
Candesartan Trials (DIRECT) were large 
randomised trials designed to assess 
whether reducing blood pressure in 
diabetic patients who did not have 
hypertension lowered the incidence/
progression of DR. The trials showed 
that there was no effect on either the 
incidence or progression of DR.  
At present, therapies for established DR 
reduce the progression of the disease 
and stabilise visual acuity. Only rarely do 
these therapies lead to improved vision.  
Treating DR can be expensive. Every 
patient also requires monthly follow-up, 
which greatly increases the number of 
clinic visits.  
The best and most affordable care 
we can provide for people with diabetes is 
secondary prevention to reduce the 
incidence of DR by means of good control 
of blood sugar and blood pressure. 
This can only be achieved if there is 
collaboration with physicians and good 
communication between eye health 
workers and patients. These measures 
will not only decrease the incidence and 
progression of DR, but also the other 
complications of diabetes, and they will 
be beneficial for every diabetes patient.  
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‘Avoiding blindness 
could be a powerful 
motivator for 
people to change 
their lifestyle for 
the better’
a volunteer checks the blood sugar of a patient in an eye clinic. FiJi
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